404 related articles for article (PubMed ID: 23163511)
1. Emerging human papillomavirus vaccines.
Ma B; Maraj B; Tran NP; Knoff J; Chen A; Alvarez RD; Hung CF; Wu TC
Expert Opin Emerg Drugs; 2012 Dec; 17(4):469-92. PubMed ID: 23163511
[TBL] [Abstract][Full Text] [Related]
2. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
3. Control of HPV infection and related cancer through vaccination.
Tran NP; Hung CF; Roden R; Wu TC
Recent Results Cancer Res; 2014; 193():149-71. PubMed ID: 24008298
[TBL] [Abstract][Full Text] [Related]
4. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
5. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
[TBL] [Abstract][Full Text] [Related]
6. Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers.
Ling M; Kanayama M; Roden R; Wu TC
J Biomed Sci; 2000; 7(5):341-56. PubMed ID: 10971133
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic human papillomavirus vaccines: current clinical trials and future directions.
Hung CF; Ma B; Monie A; Tsen SW; Wu TC
Expert Opin Biol Ther; 2008 Apr; 8(4):421-39. PubMed ID: 18352847
[TBL] [Abstract][Full Text] [Related]
8. The current state of therapeutic and T cell-based vaccines against human papillomaviruses.
Yang A; Farmer E; Lin J; Wu TC; Hung CF
Virus Res; 2017 Mar; 231():148-165. PubMed ID: 27932207
[TBL] [Abstract][Full Text] [Related]
9. Vaccines against human papillomavirus.
Lin YY; Alphs H; Hung CF; Roden RB; Wu TC
Front Biosci; 2007 Jan; 12():246-64. PubMed ID: 17127297
[TBL] [Abstract][Full Text] [Related]
10. Immunizing against Anogenital Cancer: HPV Vaccines.
Pogoda CS; Roden RB; Garcea RL
PLoS Pathog; 2016 May; 12(5):e1005587. PubMed ID: 27196109
[No Abstract] [Full Text] [Related]
11. Virus-like particles for the prevention of human papillomavirus-associated malignancies.
Wang JW; Roden RB
Expert Rev Vaccines; 2013 Feb; 12(2):129-41. PubMed ID: 23414405
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus vaccines for the prevention and treatment of cervical cancer.
Tomson TT; Roden RB; Wu TC
Curr Opin Investig Drugs; 2004 Dec; 5(12):1247-61. PubMed ID: 15648945
[TBL] [Abstract][Full Text] [Related]
13. Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma.
Devaraj K; Gillison ML; Wu TC
Crit Rev Oral Biol Med; 2003; 14(5):345-62. PubMed ID: 14530303
[TBL] [Abstract][Full Text] [Related]
14. Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer.
Farmer E; Cheng MA; Hung CF; Wu TC
Recent Results Cancer Res; 2021; 217():157-195. PubMed ID: 33200366
[TBL] [Abstract][Full Text] [Related]
15. Concerned about HPV-related cancer rise, researchers advocate boosting HPV vaccination rates.
Azvolinsky A
J Natl Cancer Inst; 2013 Sep; 105(18):1335-6. PubMed ID: 23990671
[No Abstract] [Full Text] [Related]
16. Vaccination to prevent and treat cervical cancer.
Roden RB; Ling M; Wu TC
Hum Pathol; 2004 Aug; 35(8):971-82. PubMed ID: 15297964
[TBL] [Abstract][Full Text] [Related]
17. DNA vaccines for cervical cancer: from bench to bedside.
Hung CF; Monie A; Alvarez RD; Wu TC
Exp Mol Med; 2007 Dec; 39(6):679-89. PubMed ID: 18160838
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
19. [Immune response in cervical cancer. Strategies for the development of therapeutic vaccines].
Mora-García ML; Monroy-García A
Rev Med Inst Mex Seguro Soc; 2015; 53 Suppl 2():S206-11. PubMed ID: 26462518
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and burden of HPV-related disease.
Serrano B; Brotons M; Bosch FX; Bruni L
Best Pract Res Clin Obstet Gynaecol; 2018 Feb; 47():14-26. PubMed ID: 29037457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
